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Abstract
The BREELIB nebulizer was developed for iloprost to reduce inhalation times for patients with pulmonary arterial hypertension
(PAH). This multicenter, randomized, unblinded, four-part study compared inhalation time, pharmacokinetics, and acute tolerability
of iloprost 5 mg at mouthpiece delivered via BREELIB versus the standard I-Neb nebulizer in 27 patients with PAH. The primary
safety outcome was the proportion of patients with a maximum increase in heart rate (HR) 25% and/or a maximum decrease in
systolic blood pressure 20% within 30min after inhalation. Other safety outcomes included systolic, diastolic, and mean blood
pressure, HR, oxygen saturation, and adverse events (AEs). Median inhalation times were considerably shorter with BREELIB
versus I-Neb (2.6 versus 10.9min; n¼ 24). Maximum iloprost plasma concentration and systemic exposure (area under the plasma
concentration–time curve) were 77% and 42% higher, respectively, with BREELIB versus I-Neb. Five patients experienced a
maximum systolic blood pressure decrease 20%, four with BREELIB (one mildly and transiently symptomatic), and one with
I-Neb; none required medical intervention. AEs reported during the study were consistent with the known safety profile of
iloprost. The BREELIB nebulizer offers reduced inhalation time, good tolerability, and may improve iloprost aerosol therapy
convenience and thus compliance for patients with PAH.
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Iloprost is a stable prostacyclin analogue approved for the
treatment of pulmonary arterial hypertension (PAH),1,2
a life-threatening condition characterized by vascular
remodeling and increased pulmonary vascular resistance
(PVR), ultimately leading to right heart failure.3–5
Prostacyclin analogues increase intracellular levels of cyclic
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adenosine monophosphate, thereby promoting arterial
vasodilation and inhibiting cell proliferation, inflammation,
and platelet aggregation.1,6,7
Iloprost is administered via inhalation for PAH.8–10
Inhaled iloprost has previously shown efficacy and safety
in patients with PAH both as monotherapy11–14 and in com-
bination with other PAH drugs.12,14–16 Treatment with
inhaled iloprost in PAH requires multiple inhalations—usu-
ally six to nine times per day. The I-Neb Adaptive Aerosol
Delivery nebulizer was approved for use with iloprost in
2006 and is now widely used. The estimated inhalation
time for iloprost 5 mg at the mouthpiece is 6.5min.1
However, clinical studies showed that inhalation times
with this device were prolonged in some patients,1,8,17 thus
introducing a risk of non-adherence.18
Based on recent progress in inhalation device tech-
nology,19 the BREELIB nebulizer (Vectura Group plc,
Chippenham, UK) was developed to provide a device
specifically for iloprost inhalation. It is designed to reduce
inhalation times, improve convenience, and ensure pre-
cise, targeted drug delivery to the lungs. Each time the
patient inhales, an aerosol bolus is released for 2 s followed
by aerosol-free air for 1 s. The device guides the inhal-
ation speed by LED feedback and a mechanical flow
limitation valve. An air shut-off valve provides feedback
when the target inhalation volume is reached. These
features ensure that the exact dose is delivered, nebulized
iloprost is not wasted, and suboptimal breathing patterns
are reduced.
Here we report the findings of a phase 1/2 study compar-
ing the acute tolerability and pharmacokinetics (PK) of ilo-
prost administered by the BREELIB nebulizer within a
markedly reduced inhalation time compared with inhalation
via the standard I-Neb nebulizer. The objective of the study
was to demonstrate the safety of rapid inhalation, which
should improve the convenience of iloprost aerosol therapy
and thus patient compliance.
Methods
Participants
Male or female patients with PAH (updated Dana Point
Classification 1) aged 18 years were eligible for inclusion
if they had a confirmed diagnosis of PAH (mean pulmonary
arterial pressure [mPAP]> 25mmHg, pulmonary arterial
wedge pressure, or left ventricular end diastolic
pressure< 15mmHg and PVR> 4 Wood units) and were
in World Health Organization (WHO) functional class III.
All patients were receiving inhaled iloprost 5 mg using the
I-Neb nebulizer. Patients receiving concomitant therapy
with stable doses (4 weeks) of non-PAH-specific treat-
ments (e.g., calcium channel blockers, nitrates, or diuretics)
or stable doses (3 months) of PAH-specific therapies
(endothelin receptor antagonists or phosphodiesterase-5
inhibitors) were eligible.
The study was carried out in accordance with Good
Clinical Practice Guidelines and the Declaration of
Helsinki. The protocol was approved by the ethics commit-
tees of all participating centers and all patients gave written
informed consent. The study is registered at
ClinicalTrials.gov (identifier NCT02032836).
Study design
This was a multicenter, randomized, unblinded study in four
parts comparing the inhalation time, PK, and acute toler-
ability of iloprost inhaled as a 20 mg/mL solution through
the BREELIB or as a 10 mg/mL solution through the I-Neb,
to give a 5 mg dose at the mouthpiece. Iloprost dosing for
Parts 1–4 is shown in Table 1. Briefly, in Part 1 patients
received single doses of iloprost 1.25 mg and 2.5mg via
BREELIB; any patients not tolerating these doses were to
be withdrawn. In Part 2, patients were randomized
to receive a single dose of iloprost 5 mg via each nebulizer
in a cross-over design. Inhalation times for each nebulizer
were determined. In Part 3, patients received 2 weeks of
treatment with each of the nebulizers in the same order
as they were randomized to in Part 2. Patients inhaled
iloprost approximately 6–9 times per day during each
2-week period. Part 4 was an optional long-term extension
(LTE) where patients received continuous iloprost treatment
with the BREELIB for a planned duration of up to
30 months. At the time of manuscript preparation, Part 4
was ongoing.
Table 1. Study design and dosing with iloprost in each treatment
period.
Study part Study period Study treatment
1 Day 1 Single doses of iloprost 1.25 mg
(first 11 patients) and 2.5 mg using
the BREELIB nebulizer*
2 Day 2 Two doses of iloprost 5 mg (1 with
the BREELIB and 1 with the I-Neb
in a randomized order, with a 2-h
washout in between)*
3 Days 2–29 Multiple inhalations of iloprost 5mg
as needed (approximately 6–9
inhalations per day); 2 weeks with
the BREELIB and 2 weeks with
the I-Neb, in the same order as in
Part 2
4 Months 2–30 Up to 30-month long-term exten-
sion with inhalation of iloprost
5 mg using the BREELIB as needed
(approximately 6–9 inhalations
per day)
*During Parts 1 and 2 of the study, patients continued their usual background
therapy with the I-Neb nebulizer.
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Outcome measures
The primary safety outcome was the proportion of patients
with a maximum increase in heart rate (HR) of 25%
and/or a maximum decrease in systolic blood pressure
(SBP) of 20% within 30min of completing inhalation.
Other safety outcomes included non-invasive measurement
of systolic, diastolic, and mean arterial blood pressure, HR,
oxygen saturation, adverse events (AEs), and laboratory
variables. Safety was assessed in all four parts of the study.
The main PK outcome was the area under the plasma
concentration–time curve (AUC) until last measurement
(AUC[0-tlast]) of iloprost as administered by the two nebu-
lizers. Other PK parameters included the maximum drug
concentration in plasma (Cmax), time to maximum concen-
tration (tmax), and terminal elimination half-life (t1/2).
For comparison of dose linearity, the PK parameters
AUC/dose (D), AUC(0-tlast)/D, and Cmax/D of iloprost
were derived.
Measurement of pharmacokinetic parameters
PK was assessed in Parts 1 and 2 of the study; blood samples
were taken before inhalation, at the end of inhalation, and 2,
5, 10, 20, 30, and 45min (Parts 1 and 2) and 60min (Part 2)
after the end of inhalation. Owing to the high variability of
inhalation duration, and to avoid interference with the
inhalation procedure, no blood sampling was performed
during inhalation.
Quantitative analysis of iloprost in plasma was per-
formed by high-pressure liquid chromatography and
tandem mass-spectrometric detection (LC-MS/MS) at
Nuvisan GmbH, Bioanalytics, Germany. The validation of
the method and analysis of the study samples were per-
formed in compliance with the relevant guidelines of the
European Medicines Agency,20,21 the Food and Drug
Administration,22 and the Japanese authority.23 The calibra-
tion range was from 20.0 ng/L (lower limit of quantification
[LLOQ]) to 250 ng/L (upper limit of quantification). Mean
inter-assay accuracy was in the range of 97.3–102% and
precision was 6.1%. All samples were stored at or below
20 5C and analyzed within 260 days after sample
withdrawal.
Statistical analysis
Safety data were analyzed descriptively. All patients who
received any study drug (with either or both the I-Neb
and BREELIB) were included in the safety analysis set to
assess AEs. Hemodynamic variables were evaluated in
patients completing both treatment periods of Part 2 with-
out major protocol deviations, with quantifiable iloprost
plasma concentrations and pre- and post-inhalation data
on SBP and HR for both periods. Hemodynamic param-
eters in Part 2 were analyzed by analysis of variance
(ANOVA) including sequence, period, subject, and treat-
ment effects using SAS (version 9.2, SAS Institute Inc.).
PK data were analyzed by a standard non-compartmen-
tal PK analysis method using WinNonlin (Version 5.3,
Pharsight Corporation) and WinAE 2.80 (Bayer AG) soft-
ware. All patients who completed Part 1 with two valid PK
profiles using the BREELIB nebulizer were included in the
dose-linearity analysis of iloprost with the BREELIB nebu-
lizer. The comparison of PK parameters from BREELIB
and I-Neb was analyzed by ANOVA including sequence,
period, subject, and treatment effects using SAS.
Results
Participants
Of 28 patients screened and randomized, 27 were treated
and completed Parts 1 and 2 of the study. Of these, 26
completed Part 3 (Fig. 1). Twenty-four patients had valid
data for PK evaluation; three patients in Part 2 had missing
or invalid data or major protocol deviations affecting PK
evaluation and were excluded from the analysis. Patient
characteristics and concomitant medications at baseline
are shown in Table 2.
Inhalation time
Inhalation time with the BREELIB was approximately one-
quarter that observed with the I-Neb, with median inhalation
durations of 2.6min (range¼ 1.6–3.4min) and 10.9min
(range¼ 4.3–22.1 min), respectively (n¼ 24). Inhalation
time was reduced for all patients with the BREELIB com-
pared with the I-Neb.
PK analysis
The PK of iloprost were dose proportional for the 2.5 mg
and 5 mg doses at the mouthpiece following inhalation via
Paents screened
N=28
No paents excluded
Paents randomized
N=28
Randomized but not treated
N=1
Reason: Pre-treatment AE
Disconnued
N=1
Disconnuaon in Part 3
Reason: Non-compliance
Paents treated
N=27 (13/14)
Paents compleng study
N=26 (13/13)
Fig. 1. Patient disposition. x/y values indicate that x participants were
treated in the sequence I-Neb–BREELIB and y in the sequence
BREELIB–I-Neb. AE, adverse event.
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the BREELIB (Table 3). Table 3 shows the PK parameters
for iloprost 5 mg administered by the I-Neb and BREELIB.
The plasma concentration–time profile of iloprost following
inhalation with either nebulizer could be followed for up to
30min after the end of inhalation. Cmax was reached within
2–4min after the end of inhalation for each nebulizer, fol-
lowed by an exponential decrease until the LLOQ was
reached (Fig. 2). Geometric mean Cmax values were 77%
higher for the BREELIB compared with the I-Neb
(Table 3). As the total AUC could not be reliably deter-
mined in all patients owing to the rapid decline in iloprost
plasma concentrations below the LLOQ after the end of
inhalation, the AUC(0-tlast) of iloprost was used to deter-
mine systemic exposure. Geometric mean AUC(0-tlast) was
42% higher with the BREELIB compared with the I-Neb
(Table 3). Although exposure values were higher with the
BREELIB, there was considerable overlap between the
ranges of individual exposure values for the two nebulizers.
The higher overall AUC(0-tlast) observed with the
BREELIB was mainly related to the high exposure fraction
during the first 10min after the start of inhalation, although
it should be noted that exposure was not measured during
inhalation with the I-Neb or BREELIB.
Safety
Part 1. The first 11 patients tolerated inhalation of iloprost
1.25mg and 2.5 mg well. In accordance with the protocol, the
remaining patients received only iloprost 2.5 mg. The AEs
experienced were mild, transient, and consistent with the
known safety profile of iloprost (Table 4).
Part 2. Twenty-seven patients participated in Part 2 and
were included in the safety analysis, of whom 24 received
single doses of iloprost 5 mg with each nebulizer and had
valid data for both study periods. Predefined hemodynamic
events (a maximum increase in HR of 25% and/or a max-
imum decrease in SBP of 20% within 30min of complet-
ing inhalation) or AEs of hypotension were observed more
often with the BREELIB than the I-Neb (Table 4). Four
patients (15%) experienced a decrease in SBP 20% with
the BREELIB compared with one patient (4%) with the I-
Neb. No patient had an increase in HR 25%.
AEs of hypotension (SBP 90mmHg, irrespective of
symptoms) were reported in four patients (15%) after inhal-
ation with the BREELIB (two of whom also experienced a
predefined hemodynamic event of a maximum decrease in
SBP of 20% within 30min of inhalation) and in one
patient with the I-Neb. In total, eight patients (30%) experi-
enced a hemodynamic event or hypotension: six with the
BREELIB and two with the I-Neb. Of these, only one
(4%, treated with the BREELIB) experienced symptomatic
hypotension (transient symptoms for 5–32min, mild in
severity). None of the eight patients required medical inter-
vention for decreased SBP. All eight patients continued
treatment with the BREELIB and none experienced hypo-
tension in Parts 3 or 4. One patient (4%) experienced local
irritation (cough, mild in severity, not leading to discontinu-
ation of inhalation) while using the I-Neb; no local irritation
events were reported with the BREELIB.
The maximum increase in HR was 6.5 beats per minute
(bpm) (90% confidence interval [CI] 5.2–7.9 bpm) for the
BREELIB versus 2.4 bpm (90% CI 1.1–3.7 bpm) with the I-
Neb. The mean maximum decrease in SBP was 12.9mmHg
(90% CI 10.3–15.5mmHg) with the BREELIB versus
10.1mmHg (90% CI 7.5–12.7mmHg) with the I-Neb.
These changes were mild and transient, and did not require
medical intervention. No serious AEs (SAEs) were reported
in Parts 1 and 2.
Part 3. Twenty-six patients received multiple doses of ilo-
prost with the I-Neb and 27 with the BREELIB in Part 3.
More AEs were reported with the BREELIB (52%) com-
pared with the I-Neb (27%) in Part 3 (Table 4). SAEs were
reported in two patients (7%) with the BREELIB and two
Table 2. Baseline / pre-dose characteristics of the study population.
Characteristic All patients (n¼ 27)
Age (years) 58 (16)
Sex (n (%))
Male 6 (22)
Female 21 (78)
Race (n (%))
Caucasian 27 (100)
BMI (kg/m2) 27 (7)
SBP (screening) (mmHg) 120 (20)
DBP (screening) (mmHg) 70 (10)
Patients with SBP< 100mmHg
immediately prior to dosing (n)
7
Concomitant medications
ERA (n) 25
Bosentan 17
Ambrisentan 7
Macitentan 1
PDE5i (n) 22
Sildenafil 17
Tadalafil 5
Anti-thrombotic agents (n) 27
Phenprocoumon 16
Rivaroxaban 3
Acetylsalicylic acid 3
Warfarin 2
Apixaban 1
Enoxaparin 1
Heparin 1
Data are mean (standard deviation) unless otherwise indicated.
BMI, body mass index; ERA, endothelin receptor antagonist; PDE5i,
phosphodiesterase-5 inhibitor.
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Table 3. Pharmacokinetics and dose-linearity analysis for single-dose iloprost 2.5 mg and 5mg administered with the BREELIB nebulizer and
multiple-dose iloprost 5 mg administered with the BREELIB and I-Neb nebulizers in Parts 1 and 2 of the study.
Dose linearity (Parts 1 and 2)*
2.5 mg iloprost, BREELIB nebulizer 5mg iloprost, BREELIB nebulizer
n Geometric mean Geometric CV% n Geometric mean Geometric CV%
AUC(0–tlast) (ngh/L) 24 23.5 77 24 46.6 78
AUC (ngh/L) 7y 45.0 12 8y 63.1 42
AUC(0–tlast)/D (h/L) 24 0.0094 77 24 0.0093 78
Cmax (ng/L) 24 89.1 47 24 176 58
Cmax/D (/L) 24 0.0356 47 24 0.0353 58
t1/2 (h) 11
y 0.204 27 10y 0.175 24
5mg iloprost, I-Neb nebulizer 5mg iloprost, BREELIB nebulizer
Nebulizer comparison (Part 2)* n Geometric mean Geometric CV% n Geometric mean Geometric CV%
AUC(0–tlast) (ngh/L) 24 29.1 67 24 40.9 81
AUC (ngh/L) 5y 44.6 27 7y 61.8 46
AUC(0–tlast)/D (h/L) 24 0.0058 67 24 0.0082 81
Cmax (ng/L) 24 90.2 55 24 159 60
Cmax/D (/L) 24 0.0180 55 24 0.0317 60
t1/2 (h) 5
y 0.148 28 9y 0.170 23
*The population for dose linearity (upper half of table) consists of patients completing the inhalation of 2.5mg and 5 mg iloprost in study Parts 1 and 2.
The population for the nebulizer comparison (lower half of table) consists of patients completing the cross-over in study Part 2.
yAUC and t1/2 could be determined reliably only for a minority of patients due to the rapid decrease of plasma concentrations below LLOQ.
AUC, area under the concentration–time curve; AUC(0-tlast), AUC from time 0 to the last data point above LLOQ; CV, coefficient of variation; Cmax, maximum
drug concentration in plasma after single dose; D, dose; LLOQ, lower limit of quantification; t1/2, terminal elimination half-life.
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Fig. 2. Geometric mean concentration–time curves of iloprost (linear scale; bars, geometric standard deviation) obtained after a single inhalation
of iloprost 5 mg using the BREELIB and I-Neb nebulizers. Note that blood samples were not taken for the duration of inhalation with either
nebulizer. LLOQ, lower limit of quantification.
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patients (8%) with the I-Neb (Table 4). No SAE was con-
sidered study drug-related by the investigators. No AEs of
hypotension were reported in Part 3.
Local irritation was observed more frequently with the
BREELIB than the I-Neb in Part 3; three patients (11%)
experienced cough and one (4%) experienced oropharyngeal
pain with the BREELIB, while no events were reported with
the I-Neb. All local irritations were mild in severity and did
not interfere with inhalation.
There were no deaths during Parts 1–3 of the study,
and no treatment-emergent AEs led to discontinuation of
treatment.
Part 4. Of the 26 patients completing Part 3 of the study,
25 entered the LTE. At the October 2015 data cutoff,
18 patients were ongoing in the study. The median treatment
duration was 330 days (range¼ 38–555 days) and the total
treatment exposure of the LTE population was 8287 days.
Of the seven patients (28%) who discontinued from the
study in Part 4, two patients died (both due to right ven-
tricular failure as a result of worsening PAH), four withdrew
due to AEs (lung transplantation [n¼ 3] and worsening
PAH [n¼ 1]), and one withdrew due to lack of efficacy.
The AEs leading to death or drug withdrawal were assessed
by the investigators to be unrelated to iloprost. Twenty-two
patients experienced AEs (Table 5), six of whom were
judged to be study drug-related. All study drug-related
AEs were non-serious and were known adverse reactions
to iloprost with the exception of extrasystoles, which
occurred in a patient with a history of atrial fibrillation
and extrasystoles. Hypotension was reported in two patients
(not study drug-related); one patient had a history of inter-
mittent hypotension, with baseline SBP< 90mmHg, and the
other was receiving concomitant antihypertensives. Syncope
was reported in five patients (not study drug-related). The
causes of syncope were physical stress, intercurrent infec-
tions, diabetes, orthostatic hypotension, and progression
of underlying PAH. Five patients experienced AEs of
cough, two of whom were judged to be study drug-related
and three of which were not. The reported AEs were con-
sistent with the known safety profile of iloprost and
the nature of PAH. Thirteen patients (52%) experienced
SAEs; none were considered study drug-related. The most
frequent SAEs were right heart failure, syncope, worsening
PAH, and lung transplant (Table 5).
Discussion
The BREELIB nebulizer was developed to provide a device
specifically for iloprost inhalation, to reduce inhalation
times and thereby to improve convenience for patients.
This phase 1/2 study compared inhalation time, PK, and
safety of iloprost 5 mg administered via the BREELIB nebu-
lizer and the standard I-Neb nebulizer.
These data show that inhalation time was substantially
reduced with the BREELIB compared with the I-Neb, with
Table 4. Adverse events reported in Parts 1–3 of the study.
AE (n (%)) Iloprost dose and nebulizer
Part 1
1.25 mg
BREELIB
(n¼ 11)
2.5 mg
BREELIB
(n¼ 27)
Overall
(n¼ 27)
Any AE 3 (27) 6 (22) 9 (33)
Hypotension* 2 (18) 3 (11) 5 (19)
Headache 1 (9) 1 (4) 2 (7)
Angina pectoris 0 1 (4) 1 (4)
Cough 0 1 (4) 1 (4)
Dizziness 0 1 (4) 1 (4)
Hematoma 0 1 (4) 1 (4)
Nasopharyngitis 0 1 (4) 1 (4)
Part 2
5mg
I-Neb
(n¼ 26)
5mg
BREELIB
(n¼ 27)
Overall
(n¼ 27)
Decrease in SBP 20%
within 30min of inhalation
1 (4) 4 (15) 5 (19)
Increase in HR 25%
within 30min of inhalation
0 (0) 0 (0) 0 (0)
Any AE 3 (12)y 4 (15)y 6 (22)y
Hypotension* 1 (4) 4 (15) 5 (19)
Cough 1 (4) 0 1 (4)
Dizziness 0 1 (4) 1 (4)
Feeling abnormal 0 1 (4) 1 (4)
Head discomfort 0 1 (4) 1 (4)
Hypertensive crisis 1 (4) 0 1 (4)
Part 3
5mg
I-Neb
(n¼ 26)
5mg
BREELIB
(n¼ 27)
Overall
(n¼ 27)
Any AE 7 (27)y 14 (52)y 14 (52)y
AEs occurring in> 4% of patients
Headache 2 (8) 4 (15) 5 (19)
Cough 0 3 (11) 3 (11)
Atrioventricular block
first degree
0 2 (7) 2 (7)
Hot flush 0 2 (7) 2 (7)
Palpitations 0 2 (7) 2 (7)
Respiratory tract infection 1 (4) 1 (4) 2 (7)
Any serious AE 2 (8)y 2 (7)y 4 (15)y
Pneumonia 0 1 (4) 1 (4)
Gastrointestinal hemorrhage 0 1 (4) 1 (4)
Syncope 0 1 (4) 1 (4)
Hyperglycemia 1 (4) 0 1 (4)
Hypokalemia 1 (4) 0 1 (4)
Diabetes mellitus 1 (4) 0 1 (4)
Colonoscopy 1 (4) 0 1 (4)
*Hypotension was pre-defined as SBP 90mmHg, irrespective of hypotensive
symptoms.
yPatients can have experienced more than one AE.
AE, adverse event; HR, heart rate; SBP, systolic blood pressure.
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no overlap between the ranges for the median inhalation
times of the two nebulizers. Patients with PAH are required
to inhale iloprost 6–9 times daily according to individual
need and tolerability.1 The estimated inhalation time for
iloprost 5 mg is 6.5min with the I-Neb.1 The median dur-
ation of inhalation for delivery of iloprost 5 mg with the I-
Neb in the present study was 10.9min, consistent with
reports from other clinical studies.1,8,17 Therefore, net
daily inhalation time with the I-Neb in this study equates
to 65–98 min, excluding time for preparation and cleaning
of the nebulizer. Such inhalation times may be inconvenient
for patients and could result in treatment non-compliance,
as seen with inhalation therapies in other indications.24
A key characteristic and potential advantage of the
BREELIB is reduced inhalation times, as shown in this
study, with a median inhalation time of 2.6min (equating
to a net daily inhalation time of 16–23min), a reduction of
76% compared with the l–Neb. This may improve conveni-
ence for the patient and thus their adherence to treatment,
ultimately leading to improvements in efficacy of therapy
and quality of life. Interestingly, the time required for deliv-
ery of an adequate iloprost dose with the BREELIB is in the
range seen for current treprostinil aerosol therapy for
PAH.25,26
Following inhalation with the BREELIB, the PK of
iloprost were dose proportional in the range of 2.5–5 mg.
A comparison of the 5 mg dose inhaled via the two nebulizers
showed higher AUC(0-tlast) and Cmax for iloprost with the
BREELIB compared with the I-Neb. This is consistent with
the shorter inhalation time—and thus higher dose rate—
with the BREELIB, resulting in higher mean iloprost
plasma concentrations in the first 10min after the start of
inhalation. However, it should also be noted that no PK
samples were taken during inhalation, which may have
impacted AUC evaluation. The PK of iloprost with the
BREELIB were comparable to those reported for other ilo-
prost nebulizers,27 suggesting similar pharmacodynamic
effects. The Cmax and AUC(0-tlast) of iloprost with the
BREELIB were 159 ng/L and 40.9 ngh/L, respectively.
Olschewski et al. previously compared inhalation by three
jet nebulizers. This study demonstrated decreases in
PVR and mPAP with a Cmax of 155–158 ng/L and an
AUC(0-tlast) of 47.8–54.2 ngh/L.27
The shorter inhalation times using the BREELIB were
anticipated to lead to higher Cmax values. Consequently,
acute tolerability, inferred from the incidence rate of prede-
fined hemodynamic events, and AEs were the primary out-
comes of this study. A higher incidence of hemodynamic
events was observed with the BREELIB versus the I-Neb:
four (15%) versus one (4%), respectively. The difference in
incidences is within the expected range, based on data from
the pivotal phase 3 AIR study,11 in which the incidence of
hemodynamic events was 3% (90% CI 1–8%) in patients
receiving iloprost. Thus, for this study with 24 patients, a
difference of up to three incidents was not considered to be
of significance when comparing both treatments.
Nevertheless, the data presented here point to a slightly
more pronounced impact of the BREELIB on systemic
hemodynamics compared with the I-Neb during the first
10min after inhalation, consistent with the higher exposure
immediately following inhalation via BREELIB. However,
these changes were mild, mostly asymptomatic and transi-
ent, and did not require medical intervention. Further ana-
lysis of patients with elevated HR or tachycardia at baseline
did not suggest a higher risk (i.e. more pronounced treat-
ment-emergent HR increases), and patients with a low SBP
at baseline did not have a higher risk of experiencing hypo-
tension (data not shown). Taking these data into account, it
is recommended that at initiation of iloprost treatment or
when switching from another device, the first inhalation
should be performed with 1mL of iloprost 10 mg/mL
(delivering iloprost 2.5 mg at the mouthpiece); if 2.5 mg is
well tolerated, the dose should be increased by using iloprost
20 mg/mL (delivering iloprost 5 mg at the mouthpiece).1
AEs with the BREELIB were consistent with the known
safety profile of iloprost, with no unexpected findings. More
AEs were reported with the BREELIB than the I-Neb, espe-
cially in the 2-week cross-over period of Part 3. The higher
Table 5. Summary of AEs in the long-term extension (Part 4).
AE (n (%))
All patients
(n¼ 25)
Any AE 22 (88)
AEs occurring in 20% of patients
Respiratory tract infection 8 (32)
Hypokalemia 8 (32)
Nasopharyngitis 6 (24)
Dyspnea 6 (24)
Dizziness 6 (24)
Anemia 6 (24)
Cough 5 (20)
Syncope 5 (20)
Palpitations 5 (20)
Peripheral edema 5 (20)
Nausea 5 (20)
Any AE related to the study drug 6 (24)
Any AE leading to discontinuation of treatment 4 (16)
Death 2 (8)
SAE
Any SAE 13 (52)
Any SAE, study drug-related 0
SAEs occurring in 5% of patients
Right heat failure 4 (16)
Syncope 5 (20)
Lung transplant 3 (12)
Worsening PAH 2 (8)
AE, adverse event; PAH, pulmonary arterial hypertension; SAE, serious adverse
event.
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rate of hypotension and local irritations experienced with
the BREELIB may be related to the higher initial exposure
to iloprost with the BREELIB; however, these events were
mild, transient, and well tolerated. Syncope, which was
reported in one patient in Part 3 and five patients in the
LTE, is a known adverse drug reaction associated with ilo-
prost; however, it is also a frequently observed symptom of
PAH,28 and in this study no episode of syncope was assessed
as study drug-related. No patient discontinued use of the
BREELIB during Parts 1–3, and 25 of 26 eligible patients
decided to enter the LTE with the BREELIB despite being
used to the I-Neb before study entry. Data from the LTE
support the safety and tolerability of iloprost administered
using the BREELIB; after a median treatment duration of
330 days, there have been no reports of study drug-related
SAEs.
Limitations of the study include the fact that blinding
was not possible due to the different design and appearance
of the nebulizers. Therefore, a bias in safety reporting
cannot be excluded due to patients’ familiarity with the
I-Neb. In addition, as the study population was pre-treated
with iloprost, tolerance or conditioning to the side effects of
prostanoids may have resulted in under-reporting of AEs in
comparison with treatment-naı¨ve patients. The recommen-
dation for initiation of therapy with iloprost 2.5 mg at the
mouthpiece is intended to mitigate this possibility.
Conclusions
The BREELIB considerably reduced inhalation time com-
pared with the I-Neb. As a result, higher iloprost plasma
concentrations were observed, especially within the first
10min after commencing inhalation with the BREELIB.
AEs following inhalation of iloprost with either nebulizer
were consistent with the known safety profile of iloprost.
These PK and safety data suggest that the BREELIB rep-
resents a viable option for iloprost inhalation, potentially
enhancing acceptance by patients and thereby improving
treatment compliance.
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